Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
GF/B35/EDP15
Approved by the Board on: 06 October 2016
Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board: 1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1.a. and 1.b. of Section IV to GF/B35/ER12 ("Table 1"); 2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies; 3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09; 4. Approves the additional incremental funding and implementation period recommended for the Kenya malaria disease component, and the component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02; 5. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and 6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.